We are building a programmable epigenetic platform designed to shift the body’s homeostatic set point and engineer resilience to disease. By combining DNA-taregting proteins with mRNA/LNP delivery, the platform precisely and reversibly tunes disease-driving genes without cutting or permanently altering DNA; creating the potential to address high-value targets beyond the reach of conventional therapeutics.

Rather than simply blocking downstream disease signals, we aim to reprogram upstream regulatory pathways toward a more balanced, disease-resilient state.

Our lead program aims to drug MYD88 in hemophagocytic lymphohistiocytosis (HLH), a life-threatening rare immune disorder, providing a focused path to clinical proof-of-concept for the broader platform.

Join Us!

Amir@genexgen.com